Gliomas are the most frequent primary tumors of the central nervous system, and their clinical prognosis remains very poor. Because of the characteristics of gliomas, gene therapy appears as a potentially relevant strategy for their treatment. However, the inability of viral vectors to transfer the therapeutic genes to a significantly high number of tumor cells, due to their limited diffusion and distribution, remains a critical obstacle for their application treating gliomas. We have demonstrated that the overexpression of growth arrest specific1 (Gas1) induces cell arrest and apoptosis and eliminates glioma cells in vitro and when implanted in mice. To improve the therapeutic range of Gas1, we generated lentiviral vectors coding for a soluble form of Gas1. Here, we show that cells infected with this virus produce the mutant protein, that acting both in autocrine and paracrine manners, causes death of infected and neighbor cells, thus importantly enhancing the effect of Gas1. Furthermore, the administration of this vector, or cells expressing it, inhibit the growth of tumors inoculated in mice. We present a gene therapy strategy that increases the effect of the therapeutic molecule by eliminating not just the infected cells that express Gas1, but neighbor non-infected cells.
Introduction
Gliomas have an overall incidence rate of B15 per 100 000 person-years, and their clinical prognosis remains very poor, particularly for glioblastoma multiforme, the most malignant form, with a median survival of roughly 1 year after diagnosis. 1 Although current treatments include surgical resection, chemotherapy and radiotherapy, no significant improvement in survival has occurred in years. These facts underlie the need for new therapeutic approaches for these tumors, and gene therapy is a promising one. However, the efficacy of gene therapy has been hindered by several technical aspects, and one of the most critical is the incapacity of the vectors to transfer transgenes to a sufficiently large number of cells to significantly reduce the bulk of the tumor. 2 Viral vectors are considered the most efficient systems to transfer therapeutic transgenes, but their diffusion and distribution within the brain parenchyma is very limited, thus they can only infect cells near to the site where the vector is administered. [3] [4] [5] This constraint is particularly serious in the case of gliomas, where cells migrate and infiltrate into the surrounding tissue. The migrating ability of glioma cells is one of the characteristics that reduce the effectiveness of surgical resections; thus a gene therapy approach that will affect more tumor cells than those directly expressing the therapeutic molecule will enhance its effect by eradicating the cells that produce the molecule as well as neighbor cells, by both autocrine and paracrine mechanisms.
Growth arrest specific1 (Gas1) is a protein anchored to the external cell membrane by a glycosyl-phosphatidylinositol (GPI) molecule 6 that is capable of inducing cell arrest and apoptosis of different tumor and neural cells, including gliomas. [7] [8] [9] [10] We also showed that Gas1 exhibits significant structural homology with Glial-cell-line-derived neurotrophic factor (GDNF) receptors (GFRas) and demonstrated that Gas1 inhibits GDNF-mediated intracellular signaling cascades, therefore, shutting down cellular survival pathways. [10] [11] [12] As the effect of Gas1 interfering with the function of the GFRa-GDNF-Ret complex is due to its structural similarity to GFRas, and it is known that GFRa1 can be released from cells and in this soluble form binds and interacts with GDNF, at the level of the first cysteine-rich domain of the GFRa1, 13, 14 we hypothesized that a secreted, soluble Gas1 protein, could exert its inhibitory effect both in the cells that produce soluble Gas1 and in neighbor cells, thus extending its therapeutic capacity to treat tumors. Moreover, there is a report indicating that soluble Gas1, produced in COS7 cells, is functional. 15 Taken all this information together, we decided to generate Tetracycline-inducible lentiviral vectors capable of expressing a mutant, secretable, form of Gas1 and to test the capacity of this protein causing growth arrest and apoptosis of glioma cells. The lentiviral vector encodes a Gas1 protein truncated at arginine 315, lacking the GPI consensus sequence, thus, this protein will not be anchored to the cell membrane, and will be secreted from the cell. 14, 16 Lentiviral vectors effectively infected C6 glioma cells, which produced a protein capable of inducing cell death in in vitro assays. Conditioned media taken from infected cultures caused cell death in independent cultures of glioma cells. Moreover, we showed that Gas1 was responsible for the effect, because when Gas1 was immunoprecipitated from conditioned medium, the medium without Gas1 did not prevent cell proliferation. Finally, we directly administered both the Gas1-producing lentivirus, and infected Gas1-producing cells to gliomas implanted in nude mice, and observed significant inhibition of tumor growth. Our results show that the lentiviral-mediated transfer of a secretable form of Gas1 effectively induces cell death by autocrine and paracrine mechanisms, and consequently importantly enhances the potential capacity of Gas1 as a potential adjuvant for the treatment of gliomas.
Materials and methods

Construction of plasmids expressing full-length and truncated forms of Gas1
To generate full-length and truncated forms of Gas1 we amplified, by PCR, the different cDNA fragments from the pGfa2-Gas1 vector. 7 Four fragments were generated: two starting from the site of the initiation of translation up to the codon for Arginine 315, thus obtaining the truncated form, lacking the GPI consensus signal, and two full-length fragments that included up to phenylalanine 345, the last amino acid of the Gas1 sequence. However, one of each type of constructs (full length and truncated) had a stop codon in the 3 0 oligonucleotide to detain translation, and the other pair of constructs had no stop codons, thus when subcloned into the pENTRTOPO expression vector (Invitrogen, Carlsbad, CA), the V5 epitope tag would also be expressed as a fusion protein (Figure 1 ). The fragments are denominated gas1, for the full-length sequence; gas1-V5 for the fusion protein with the V5 epitope; tgas1, for the truncated form and tgas1-V5 for the truncated form with the V5 epitope. The 5 0 PCR oligonucleotide was the same for all reactions, and contained a CACC sequence for directional subcloning into the pENTRTOPO vector, included a Kozak sequence, and seven bases corresponding to the 5 0 end of gas1 (5 0 CACCGCGATGGTGGCCGC3 0 ); the sequences corresponding to the 3 0 end of each of the fragments are the following: truncated forms (5 0 -ATACCCGGACCCG CGTCC-3 0 and 5 0 -CCCGGACCCGCGTCCATT-3 0 ), and full length (5 0 -GACGAACCCGGCGAGAAA-3 0 and 5 0 -GACGAACCCGGCGAGAAAATT-3 0 ). To amplify, by PCR, the different fragments, the temperature and cycles were the following: 94 1C (1 cycle, 5 min), 94 1C, 63 1C (35 cycles) and 72 1C for denaturalizing, alignment and extension (1 min each step), respectively, and a final extension step 72 1C (1 cycle, 10 min). The vectors were sequenced to confirm the absence of unwanted mutations. Subsequently, the four input vectors were subcloned, according to the manufacturer's instructions, by homologous recombination, into the lentiviral vector pLenti/TO/ V5-DEST (Invitrogen). In this vector, the expression of the gas1 cDNAs is driven by the CMV promoter; however, the lentiviral promoter also possesses a consensus repressor sequence, thus when the repressor element is co-infected in the same cells, transgene transcription is inhibited, but it is activated in the presence of Tetracycline, thus allowing gene expression when the viral construct is used, and a Tetracycline-inducible system when both vectors are present in the same cells.
Transfection of Gas1-expressing plasmids
To corroborate that the vectors expressed both a fulllength Gas1 protein as well as a truncated, secretable, Gas1 variety, they were transfected into rat glioma C6 cells, and their effect on cell proliferation was determined, as a preliminary step before the construction of the lentivirus, as in the lentiviral pLenti/TO/V5-DEST plasmids, the expression of transgenes in eukaryotic cells is driven by the CMV promoter.
In all, 1 Â 10 6 C6 cells were seeded in 60 mm plates and grown until they reached a confluence of 80-90%, as Figure 1 Schematic representation of the different forms of Gas1. Full-length protein, including Phe 345 (Gas1); the truncated, soluble form (tGas1) including Arg 315, and the fusion proteins for each one of the forms, containing the V5 epitope (Gas1-V5 and tGas1-V5).
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A López-Ornelas et al previously described. 7, 9 After 24 h, cells were transfected using Lipofectamine 2000 (Invitrogen) with each of the four lentiviral construction plasmids. As a control, one plate was treated only with Lipofectamine 2000 and another one was only exposed to the media changes specific to the transfection protocol. All transfections were carried out under the same conditions: 8 mg of plasmid and 24 ml of Lipofectamine 2000. For some experiments, 48 h after transfection, the culture medium of transfected cells was collected and filtered with 0.22 mm filters (Millipore, Bedford, MA), for further experiments. Viable transfected cells were counted using Trypan blue; proteins and RNA were isolated using Tripure (Roche, Indianapolis, IN) to perform western blot analysis and RT-PCR, respectively, as previously described, to determine the expression of the transgenes and the different forms of Gas1. 10 The medium collected from each of the cultures was transferred as conditioned medium to independent cultures of proliferating C6 cells. For this assay, 300 000 cells were seeded in 35 mm plates and grown until a confluence of 80%. Forty-eight hours after treatment, cells were counted using the Trypan blue technique. As controls for the expression of the gas1 gene and protein, SH-SY5Y human neuroblastoma cells, that express Gas1 24 h after serum withdrawal, were used as previously described. 12 
RT-PCR
To determine the expression of the different gas1 fragments, total RNA was isolated from transfected, infected cells and tumors, transcribed into DNA using reverse transcriptase M-MLV (Invitrogen). The PCR reaction was performed under the same conditions previously described in the construction of plasmids and using as primers the oligonucleotides originally used to amplify the fragments from the pGfa2-Gas1 plasmid. As controls non-treated, Lipofectamine 2000 treated without DNA and non-infected cells were used. Expression of b-actin and lacZ was determined as previously described. 10, 12 Western blot analysis The isolation of proteins from transfected, infected cells, non-treated cells and tumors was performed using a commercial kit (Tripure) (Roche). Protein quantification was performed using the bicinchoninic acid method (Pierce, Rockford, IL). An anti-Gas1 polyclonal primary antibody (Proscience, Poway, CA) was used at a dilution of 1:200 and incubated for 12 h at 4 1C, as previously described. 10, 12 The secondary antibody (Jackson ImmunoResearch, West Grove, PA) (goat anti-rabbit) was used at a dilution of 1:4000 and incubated for 1 h at room temperature. As a positive control, we used an anti-bactin antibody, 17 as previously described. 9, 10 Proteins were revealed using a Western Lightning Plus-ECL Kit (PerkinElmer, Waltham, MA). Images were digitally captured with a BioDoc-It Imaging System (UVP, Upland, CA).
Construction of lentiviral vectors
Viral producer cells
The 293FT cells (Invitrogen) were used for the packaging of lentivirus. Cells were grown in DMEM with high glucose (Invitrogen), with 10% fetal bovine serum (Invitrogen), MEM non-essential amino acids 0.1 mM (Invitrogen), 6 mM L-glutamine (Sigma-Aldrich, St Louis, MO), 1 mM sodium pyruvate (Invitrogen) and 1% Penicillin/Streptomycin (PAA, Ontario, Canada).
Construction of lentiviral vectors
Briefly, DNA complexes were prepared using Lipofectamine 2000, and the virus was obtained as described by the manufacturer (ViraPower T-Rex Lentiviral Expression System, Invitrogen). Two complexes were formed for the subsequent construction of lentivirus; one virus with the sequence for the truncated, secretable gas1 and the other virus expressing secretable gas1 together with the V5 epitope as a fusion protein, and finally the virus with the repressor element. As a control, a lacZ-expressing lentivirus was also generated (the lentivirus with lacZ and the repressor element were constructed following the manufacturer's protocol). The viral titers were obtained based on the sensitivity of the cells to Zeocin (250 mg ml À1 ) (Invitrogen) for the lentivirus coding for both truncated and truncated-V5 forms of Gas1, and with Blasticidin (5 mg ml À1 ) (Invitrogen) for the virus with the repressor element, according to the following equation: CFU per ml ¼ p Â 20 Â 10X; where CFU is colony forming units, p is the number of colonies per dilution of viral stock, 20 is a correction factor to express CFP per ml (1000 ml per inoculated volume) and 10X is the lowest dilution used. For in vitro experiments, C6 cells were infected with lentivirus with tgas1 and tgas-V5 (multiplicity of infection (MOI) 1-10) in the presence of Polybrene (Sigma-Aldrich), 6 mg ml À1 for 24 h, medium was removed, cells were washed three times with phosphate-buffered saline and incubated in complete medium. Forty-eight hours after infection, cell viability was evaluated with the Trypan blue technique, then culture medium was collected and applied as conditioned medium to proliferating cultures of C6 cells, as previously described.
Stably infected C6 cells C6 cells were infected with the lentivirus containing the repressor element of expression (MOI 10) and cells were selected with Blasticidin (Invitrogen) (5 mg ml
À1
). Subsequently, these cells were infected with the lentivirus expressing the truncated, secretable, form of Gas1 (MOI 10) and selected with Zeocin (Invitrogen) (250 mg ml À1 ); the selection with Blasticidin was also maintained.
Southern blot analysis
Genomic DNA was obtained from both stably infected C6 cells and from control non-infected cells, digested and ran in a 0.6% agarose gels. DNA was transferred onto nylon membranes (Amersham; Piscataway, NJ) and hybridized with a dioxigenin-labeled riboprobe transcribed with T7 from a PCR template generated from the Soluble Gas1 inhibits glioma growth A López-Ornelas et al tGas1 lentiviral vector (Epicentre, AmpliScribe T7, T3 and SP6 High Yield Transcription Kits, Madison, WI), for 18 h at 60 1C. Membranes were incubated with an antibody against dioxigenin (Roche) 1:5000, and signals revealed using a Western Lightning Plus-ECL Kit (PerkinElmer). Images were digitally captured with a BioDoc-It Imaging System (UVP).
Immunocytochemistry
In all, 1 Â 10 6 stably infected C6 cells producing tGas1 were grown until they reached 80-90% confluence in 60 mm plates and were subsequently divided into three groups; one was treated with Tetracycline (Invitrogen) (2 mg ml À1 ), the second group did not receive Tetracycline and the last group consisted of control non-transduced C6 cells. After 48 h in culture, cells were fixed with 4% p-formaldehyde prepared in phosphate-buffered saline (pH ¼ 7.4) and incubated with a polyclonal antibody against Gas1 (Proscience) (1:200). 10 The secondary antibody was a biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA) (1:300). Proteins were revealed with fluorescein streptavidin (Vector Laboratories) (1:200) and cells were counterstained with 4,6-diamino-2-phenyldole (Vector Laboratories) to expose the nuclei. An Olympus BX-51 microscope and the Image-Pro Plus program Version 4.5 (MediaCybernetics, Bethesda, MD) were used. SH-SY5Y were cultured and assayed as previously described. 12 Immunoprecipitation Cells were seeded as previously described for immunocytochemistry, culture media were collected and incubated with the antibody against Gas1 (Proscience) 9, 12 and then immunoprecipitated with Tachizorb (Roche) following the manufacturer's instructions; as a control, medium was incubated with an unrelated polyclonal antibody, in this case, against glial fibrillary acidic protein (Dako, Carpinteria, CA). After immunoprecipitation, western blot assays to detect Gas1 were performed as previously described, including the control medium. The medium from tgas1-infected cells with or without Tetracycline and from non-infected control cells subjected to the immunoprecipitation protocol were applied to cultures of C6 cells, and after 48 h, cellular viability was evaluated by the Trypan blue assay.
BrdU incorporation
Cells were plated as previously described for the immunocytochemistry assay, and incubated in the presence of 50 mM of BrdU (Roche) for 6 h at 37 1C. Twentyfour hours after transduction, cells were analyzed for BrdU incorporation. A BrdU staining kit (Invitrogen, Camarillo, CA) was used according to the manufacturer's instructions. A total of 200-300 cells per coverslip were examined to determine the percentage of cells that incorporated BrdU.
Apoptosis assay
To determine apoptotic death, 48 h after infection with the tgas1 lentivirus, the number of cells undergoing apoptosis was determined using an in situ cell death detection kit (TUNEL), based on the TdT-mediated dUTP nick ending labeling, following the manufacturer's instructions (Roche). Twenty fields from three independent experiments were counted.
In vivo transduction with lentivirus-expressing secretable Gas1
Experiments were performed according to current Mexican legislation NOM-062-ZOO-1999 (SAGARPA) and in agreement with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH) and internal (Cinvestav) guidelines. In all, 1 Â 10 6 C6 cells were subcutaneously inoculated into the dorsal flank of 6-8-week-old nude (nu/nu) mice, as previously described. 8, 9 When the tumors reached 4-5 mm (large axis), animals were divided into three groups; one received three doses of 5 Â 10 5 viral particles (v.p.) expressing tgas1, another received the lacZ-expressing virus (5 Â 10 5 v.p.) and the last, control group, received 100 ml of medium. Each dose was injected intratumorally every third day, the tumor diameter was measured every third day for 10 days, and the volume was calculated according to the following equation:
where D max and D min represent the large and small axis, respectively. After 10 days of starting the treatment, mice were euthanized and tumors were extracted. Tumor RNA and protein were isolated for RT-PCR and western blot assays, respectively, as previously described. For the second group of experiments, 5 Â 10 5 C6 cells were mixed with 5 Â 10 5 C6 cells stably expressing the tgas1 lentivirus together with the repressor and were injected into the flanks of nu/nu mice, as previously described. When tumors reached 4-5 mm large axis, mice were divided into two groups. One group received three injections of Tetracycline (2 mg kg À1 in 100 ml of saline solution) every third day, and the other group received the same volume of vehicle. Tumor volume was determined as previously mentioned, and 10 days starting the treatment mice were euthanized.
Results
Construction and expression of gas1 transgenes
We obtained four different cDNA fragments expressing full-length and truncated gas1 sequences, amplifying by PCR the fragments from the pGfa2-Gas1 plasmid.
7 Figure 1 shows the schematic representation of the Gas1 proteins: two proteins contain the full-length Gas1 aminoacid sequence, Gas1, and the other is a fusion protein of Gas1 together with the V5 epitope, Gas1-V5. The other two proteins contain the truncated, secretable, form of Gas1, one as the truncated Gas1 protein, tGas1, and the other one, tGas1-V5, is the truncated Gas1 protein with the V5 epitope.
Each DNA fragment was directionally subcloned into the pLenti/TO/V5-DEST expression vector and transfected into C6 glioma cells. Figure 2a shows the expression of each of the constructs as demonstrated by RT-PCR.
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As can be observed, the sizes of the products obtained from cells transfected with the complete gas1 sequence (gas1 and gas1-V5) are larger than the truncated, secretable forms (tgas1 and tgas1-V5); no expression of the transgene was observed in control non-transfected cells, or cells subjected to the transfection protocol (Lipofectamine) without cDNA (Figure 2a , lower panels).
To corroborate the appropriate expression of the transgenic proteins, we performed western blot analysis of transfected cells. Figure 2b shows the expression of Gas1 in transfected cells, here we can also observe that the different forms of Gas1 are of the expected sizes, that the Gas1 forms are larger than the tGas1 constructs (B3 kDa), and the V5-fusion proteins are larger that the Gas1 and tGas1 forms without the V5 epitope (B1.4 kDa). To determine the molecular size of the transgenic proteins, we used commercial size markers, but also compared them with the endogenous Gas1 protein obtained from SH-SY5Y cells grown in the absence of serum. 12 The next step was to determine the capacity of the transgenic human Gas1 reducing the number of viable cells. C6 cells were seeded and transfected with the different constructs. Figure 2c shows that all forms of Gas1 reduced the number of viable cells with respect to control. To determine whether the capacity reducing the number of viable cells could be transferred to independent cell cultures, we took conditioned media from cultures of transfected cells and substituted the media of nontransfected cells with the conditioned media. A doseresponse curve was constructed substituting different amounts of the medium of the independent cultures (from 25% of the volume to complete substitution of the medium, 100%) with conditioned medium. Figure 2d shows that there are no significant differences in the number of viable cells, when comparing the medium from control cells, cells subjected to Lipofectamine, or cells expressing full-length Gas1, whereas media from cells expressing the truncated forms of Gas1 significantly reduce the number of viable cells. The effects were seen from the lowest level of substitution of medium (25%), and in the tGas1, the number of viable C6 cells decreased when the volume of conditioned media increased more (Figure 2d) . Interestingly, the form of truncated Gas1 without the V5 epitope is more effective that the fusion protein with the V5 epitope (Figure 2d ). This result indicates that the cell growth inhibitory effect is caused by soluble Gas1. We also determined the capacity of the conditioned medium of C6-transfected cells to arrest the cell cycle, of control non-transfected C6 cells, and observed that the media from all transfected cultures had an effect, but that the truncated forms of Gas1 were more effective inducing this outcome than the full-length forms, and that tGas1 achieves a better result when compared with tGas1-V5 (Figure 2e) , similarly to what had been observed regarding their ability to decrease the number of viable cells (Figure 2d ).
Expression and effect of tgas1-expressing lentivirus
After determining the effect of both the full-length and truncated forms of Gas1 reducing the number of viable transfected C6 cells and also from the conditioned media obtained from those cells, we concluded that the truncated forms of Gas1 were effective reducing both the viability and the proliferation of cells of independent cultures, thus suggesting that the soluble forms of Gas1 were responsible for this effect. To increase the efficiency of the transfer of the transgenes, as well as to obtain a system to regulate their expression, we constructed lentiviral vectors, in which the expression of the transgenes can be induced by the administration of Tetracycline. It is worthwhile to remark that the lentivirus, in the absence of the repressor element of transcription, will express the transgene under the control of the CMV promoter, and that it is when co-expressed with the repressor that the transgene will only be transcribed in the presence of Tetracycline. In order to determine the number of vector copy number per cell, we performed Southern blot analysis of stably infected C6 cells and found four copies of the tgas1 vector (Supplementary Figure 1) . C6 cells were infected with two lentivirus-expressing tGas1 and tGas1-V5, respectively. The expression of the transgenes was confirmed by RT-PCR (Figure 3a) and that of the transgenic protein by western blot analysis, where we can observe that the transgenic proteins are smaller than the endogenous full-length human Gas1 protein obtained from serum-starved SH-SY5Y cells (Figure 3b ). We also determined the effect of the expression of the different forms of truncated Gas1 on the number of viable cells, in cells infected with the viral vectors, and that induced using media from cultures of infected cells. We can observe that the number of viable cells is significantly lower in cells infected with both tGas1 and tGas1-V5 lentivirus, compared with control, and that media from infected cultures also reduces the number of viable cells with respect to control, that is medium from non-infected cells (Figure 3c ). We can also perceive that the effect of the tGas1 form is greater than that of the tGas1 form expressing the V5 epitope (Figure 3c) . We assayed the capacity of the soluble forms of Gas1 to inhibit the proliferation of cells, infected with the virus, and of the conditioned media obtained from infected cells, as determined by the incorporation of BrdU (Figure 3d ). Although both forms of truncated Gas1 inhibit cell proliferation, tGas1 was more capable than tGas1-V5 inhibiting proliferation of C6 cells. We constructed response curves using different MOI for each virus and assays, from 1 to 10 MOI, obtaining the more pronounced effects with a MOI of 10 (Figures 3c and d) . Based on the previous information, we decided to use the tGas1 virus at a MOI of 10 for the following experiments.
We have previously shown that Gas1 induces apoptosis and cell arrest of glioma cells, 9, 10 and decided to determine whether the tGas1 form acts in the same manner. We observed that tGas1 induces a large increase of apoptotic cells, as determined by the TUNEL assay, when compared with control cells, and that the medium of infected cells can also induce apoptosis of a large number of cells in independent cultures (Figure 4 ). tGas1 from infected cells. These results are in agreement with our previous data, [7] [8] [9] [10] and further support the concept of the apoptotic effect induced by the secretable form of Gas1 (tGas1) that acts on the cells that express the transgene, as well as in a soluble form in the medium of transfected and infected cells expressing this truncated Gas1 protein.
To confirm the capacity of the tgas1 lentivirusexpressing tGas1 in a regulated manner, we generated a stable cell line infected with the tGas1 lentivirus, and with the virus containing the repressor element of transcription. Cells were selected in the presence of Blasticidin and Zeocin, and maintained in the presence of the antibiotics. We determined the expression of tgas1 in infected cells both in the presence and absence of Tetracycline (2 mg ml À1 of medium), and observed that tGas1 was only expressed in infected cells in the presence of Tetracycline, as determined by RT-PCR (Figure 5a ). We also verified the expression of the tGas1 protein exclusively in infected cells receiving Tetracycline, as ascertained by both western blot analysis and immunocytochemistry, as positive controls for expression and protein size, we used the SH-SY5Ycells, which express Gas1 after serum withdrawal (Figures 5b and c) .
Definitive demonstration of the presence of soluble Gas1, as well as its capacity inhibiting cell growth and inducing cell death is a necessary prerequisite to substantiate a gene therapy approach based on the concept of a Gas1 protein that can induce both autocrine and paracrine effects. To achieve these objectives, tGas1 was immunoprecipitated from the medium of stably infected cells, in the presence and in the absence of Tetracycline. Figure 6a shows that tGas1 was only immunoprecipitated from the media of cultures of infected cells in the presence of Tetracycline, and not from medium of control non-infected cells, or from infected cells grown in the absence of the drug. As positive controls we used endogenous Gas1 obtained from serumstarved SH-SY5Y cells, as previously described, tGas1 isolated from transfected cells, and as negative control, we showed that the use of a non-related antibody does not precipitate tGas1 (Figure 6a) . Furthermore, we showed that medium from which tGas1 had been removed by immunoprecipitation had no effect on cell growth, with respect to cells cultured with medium from control noninfected cells, whereas medium from Tetracycline-treated tGas1-infected cells, induced a significant decrease in the number of viable C6 when compared with both control and medium in which tGas1 had been removed (Figure 6b ). Taken together, our data demonstrate that tgas1-infected cells produce a truncated form of Gas1, under the control of an inducible promoter, which is released to the medium, in a soluble form that can inhibit the growth of glioma cells.
In vivo effects of tGas1
To ascertain the therapeutic potential of tGas1, we examined the effect of the gene transfer of tgas1 determining the growth of C6 cells inoculated in athymic nude mice. C6 cells were injected into the flanks of nu/nu mice, and when the tumors reached 4-5 mm of the longer axis, we administered intratumorally, vehicle (control), lacZ-expressing virus, or tgas1 virus. Treatments were applied every other day for a total of three injections, and we determined the growth of the tumor for 10 days after initiating the treatment. Tumors receiving the tgas1 lentivirus showed a 74% reduction in growth, compared with non-treated controls, and were significantly different from both control and lacZ-infected tumors (Figure 7a) . Moreover, after treatment, mice were euthanized and expression of transgenes assessed in dissected tumors. Figure 7b shows the expression of the tgas1 and lacZ transgenes exclusively in tumors receiving the corresponding virus, and in Figure 7c , we observed that tGas1 was only expressed in tgas1-infected tumors. These results demonstrate that the lentivirus-mediated transfer of the tgas1 transgene is very effective in inhibiting the growth of gliomas in an in vivo mouse model. Cell proliferation determined by BrdU incorporation of C6 cells after infection with tgas1 and tgas1-V5 virus, or after taking conditioned medium from infected cells and substituting it, in control noninfected cells, using different MOI, controls are non-infected C6 cells, or medium from non-infected cells, n ¼ 3. Data are means±s.e.m. Analysis of variance (ANOVA) followed by Tukey's test. *Po0.05, **Po0.01 ***Po0.001, with respect to control.
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To further determine the capacity of tGas1 as a potential therapeutic molecule, we inoculated a mixture of C6 cells with C6 cells stably infected with the tgas1 lentivirus, into the flanks of nu/nu mice. When tumors reached the sized previously described, we treated one group of mice with Tetracycline (2 mg kg À1 ) to induce the expression of the transgene, whereas the other group received the same volume of vehicle. Figure 7d illustrates that there is a significant reduction (60%) in the volume of the tumors receiving Tetracycline, compared with saline controls, thus showing that the Tetracyclineinduced production of secretable Gas1 is effective diminishing glioma cell proliferation (Figure 7d ).
Discussion
Gliomas, particularly glioblastoma multiforme, have a very poor prognosis that has not improved for decades. Although current treatments include sophisticated surgical approaches, radiotherapy and chemotherapy, 1 the ability of tumor cells to infiltrate into the brain parenchyma as well as their enhanced resistance to drugs and radiation, deter the efficacy of existing treatments. Gene therapy offers a promising approach for the treatment of brain tumors, particularly of gliomas, because it can deliver therapeutic genes into tumors, that very rarely metastize outside of the CNS. Viral vectors have been the system most widely used to deliver transgenes in both preclinical and clinical trials, and though they appear safe, clinical results have not yet generated a viable alternative to current glioma treatments. 18, 19 The most common therapeutic transgene used for glioma gene therapy, both experimentally and in clinical trials, has been the herpes thymidine kinase (HSV-tk) gene. [20] [21] [22] The product of the HSV-tk gene transforms the prodrug ganciclovir to a precursor that arrests DNA replication, inducing cell death. Interestingly, the effects of this type of vectors are amplified by the bystander effect, caused by the passage of the toxic metabolites to cells connected by gap junctions. [23] [24] [25] This effect increases the therapeutic capacity of this approach; however, a limitation to this system is that the level of intercellular communication varies in different tumors, and may even be blocked in the later stages of carcinogenesis. 24, 26, 27 We consider, as we will discuss in more detail presently, that the procedure we put forward in this paper shows improvements with respect to the transfer of HSV-tk, because it affects neighboring cells that need not to be joined by gap junctions, thus increasing its range of therapeutic activity.
There are several factors that need to be considered for viral vectors to deliver the therapeutic transgene to sufficient tumor cells to induce a significant beneficial effect in patients. Physical barriers and immune responses inhibit the distribution of viral vectors. On the other hand, the short half-life of some virus, like retrovirus, also affect their therapeutic capacity. 28, 29 Virus diffuse passively once they are administered into the tissue, and their inadequate distribution and propagation within the tumor diminish their therapeutic capacity. 30 Viral vectors are very large compared with chemotherapeutic agents (over 100-fold), causing their distribution within the tumor to be very limited, thus the penetration of these vectors from the site of injection or from the vasculature is severely restricted. 4, 19 The extracellular matrix has an important role limiting the distribution of viral vectors within the tumor, and experimental approaches to modulate the matrix, and thus allowing a better distribution of the virus have been proposed. 31, 32 Another strategy to obtain a more complete and homogeneous distribution of the therapeutic agent is to use soluble molecules that can be released from cells expressing the transgene, 33 and in this manner more freely diffuse within the tumor, thus enhancing the beneficial effect of the treatment. Gas1 is a molecule that can induce cell arrest and apoptosis of different tumor cells, [34] [35] [36] including glioma cell lines and human primary gliomas. [7] [8] [9] [10] Bioinformatics analysis uncovered significant structural homology between Gas1 and GFRas. 11 Based on this Soluble Gas1 inhibits glioma growthinformation, we showed that the effect of Gas1 arresting cell cycle and inducing apoptosis is caused by its ability inhibiting the GDNF-mediated intracellular signaling cascade, a mechanism consistent with the effect of GDNF inducing glioma proliferation. 10, 12, 37 It has been reported that the carboxy terminal domain of Gas1 is not necessary for this molecule to induce growth arrest, and that a soluble form is active. 15 These data allowed us to hypothesize that a secreted, soluble, form of Gas1 would arrest cell cycle and induce apoptosis in cells expressing the transgene, but also in neighbor cells not expressing it. To obtain a secretable form of Gas1, we generated truncated forms of Gas1, lacking the GPI-link consensus sequence, so these forms of Gas1 will be secreted from the cells. 14, 38, 39 The autocrine and paracrine effects of Gas1 will significantly increase its therapeutic capacity, by allowing the diffusion and distribution of the therapeutic molecule away from producer cells. To reach this objective we generated lentivirus expressing a truncated form of Gas1 (Arg 315), and determined that infected cells release a soluble form of Gas1 that can induce cell arrest and apoptosis when transferred to independent cultures of C6 cells. Furthermore, the intratumoral injection of the tgas1 lentivirus inhibited the growth of C6 cells inoculated in nu/nu mice. Finally, we also observed decreased tumor growth, when a mixture of non-infected C6 cells and cells stably infected with the tgas1 virus were inoculated together in mice and were administered with Tetracycline, when compared with mice undergoing the same protocol, but that did not receive Tetracycline. This experiment shows that tGas1 produced in infected cells inhibits cell growth and induces apoptosis of neighbor cells.
There are reports indicating that soluble apoptogenic molecules, like TRAIL, applied into gliomas are effective reducing tumor growth. [40] [41] [42] Thus, a potentially relevant form of application is the concept of injecting tGas1-producing cells into tumors. A possible source of the cells are cells from the same tumor, other somatic cells from the same patient, or from a different source, so the secreted protein could inhibit the growth of the tumor, and in the case of applied tumor cells would also kill the genetically modified cells and increase the safety of the system. The capacity of regulating the production and release of the therapeutic molecule will also facilitate control of the treatment, both temporally, and if cells can be marked and traced in the patient, also by its localization in the brain. As a first attempt to explore these potential therapeutic strategies, we injected a mixture of C6 cells, and stably infected C6 cells into nude mice, and determined the effect of the administration of Tetracycline in the growth of the tumors. As seen in Figure 7d , there is a significant reduction in the growth of the tumors that received Tetracycline compared with control mice. This experiment shows it is feasible to regulate the expression of tGas1 from infected cells in an in vivo model, and inhibit tumor growth.
In the present work, we have demonstrated that a truncated form of Gas1, produced in transfected or The culture medium of control C6 cells was changed with media from control non-infected, from medium of C6 stably infected cells in the presence of Tetracycline, from which tGas1 had been removed by immunoprecipitation, IPtGas1, and from infected cells from which tGas1 was not immunoprecipitated, tGas1. Analysis of variance (ANOVA) followed by Tukey's test. *Po0.05, **Po0.01, n ¼ 3.
Soluble Gas1 inhibits glioma growth
A López-Ornelas et al infected cells, can be secreted into the medium, and induce cell arrest and apoptosis of other cells not expressing the therapeutic transgene. Furthermore, the application of the lentiviral vector, or cells infected with this virus inhibit the growth of tumors inoculated in mice. We consider that the results shown here support the potential use of Gas1 as an adjuvant in the treatment of gliomas, and when we consider the soluble nature of tGas1, expand its therapeutic capability. ) and the control group only received vehicle (saline solution). Results are means ± s.e.m. Arrows show the different applications of Tetracycline. ANOVA followed by Tukey's test. **Po0.01, ***Po0.001 compared with medium group, n ¼ 4-5 mice per group.
